Director Anne Prener of Keros Therapeutics, Inc. filed a Form 4 on November 19, 2026, disclosing the sale of 575 shares of common stock on November 17, 2026, executed under a Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Anne Prener, identified as a Director of Keros Therapeutics, Inc. (NASDAQ:KROS)
  • First sale: 433 shares disposed of on November 17, 2026, at a weighted average price of $10.77, with individual transaction prices ranging from $10.02 to $10.98 inclusive
  • Second sale: 142 shares disposed of on November 17, 2026, at a weighted average price of $11.03, with individual transaction prices ranging from $11.03 to $11.04 inclusive
  • Remaining holdings: 12,637 shares of common stock held directly following both transactions
  • Trading plan: Both transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Prener on August 6, 2026

Anne Prener's November 2026 Share Sales Under 10b5-1 Plan

According to the Form 4 filed with the SEC on November 19, 2026, Anne Prener, a director of Keros Therapeutics, Inc., disposed of a combined 575 shares of common stock on November 17, 2026. The filing indicates both transactions were carried out pursuant to a Rule 10b5-1 trading plan that Prener adopted on August 6, 2026. Transaction codes on the filing are listed as "S," denoting open-market sales.

The first transaction involved 433 shares sold at a weighted average price of $10.77 per share. The filing notes that these shares "were sold in multiple transactions at prices ranging from $10.02 to $10.98 inclusive." The second transaction covered 142 shares sold at a weighted average price of $11.03, with individual prices ranging from $11.03 to $11.04 inclusive. In both cases, the filing states that full information on the number of shares sold at each separate price is available upon request to the issuer, any security holder, or SEC staff.

Following both reported transactions, Prener's direct beneficial ownership of Keros Therapeutics common stock stood at 12,637 shares, according to the filing. No derivative securities were reported in Table II. The Form 4 was signed by Esther Cho as Attorney-in-Fact on November 19, 2026.

What Was Disclosed

The filing disclosed two open-market sales of Keros Therapeutics common stock by Director Anne Prener on November 17, 2026, totaling 575 shares across two transactions at weighted average prices of $10.77 and $11.03, executed under a pre-established Rule 10b5-1 plan.